Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fasting blood glucose with or without other comorbidities

Trial Profile

A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fasting blood glucose with or without other comorbidities

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms PRADO
  • Sponsors Sanofi

Most Recent Events

  • 19 Jan 2022 This trial has been completed in Greece (End Date: 04 Feb 2009), according to European Clinical Trials Database record.
  • 05 Oct 2021 This trial is completed in france (Global End Date: 2009-02-04), according to European Clinical Trials Database record.
  • 27 Jul 2020 This trial is completed in UK (Global End Date: 24 Oct 2008), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top